Summary & Overview
CPT 0074U: CYP2D6 Trans‑duplication/Multiplication Targeted Sequence Analysis
CPT code 0074U designates a proprietary laboratory assay for CYP2D6 trans–duplication/multiplication non–duplicated gene targeted sequence analysis developed by the Mayo Clinic Laboratory. As a PLA follow-up test to 0070U, it is used when standard testing fails to determine a patient’s CYP2D6 genotype, which can influence metabolism and dosing considerations for multiple medications. Nationally, targeted pharmacogenomic testing like this supports precision medicine and can impact prescribing decisions across specialties that manage drugs metabolized by CYP2D6.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and lab setting for the test, payer coverage context, and what to expect in benchmark and policy content. The publication addresses billing and reporting specifics for a PLA code, payer alignment and common modifier usage, and clinical context linking CYP2D6 genotype resolution to therapeutic implications. Where input data is missing, the report notes that specific taxonomies, ICD-10 mappings, and related codes are not available in the source.
Billing Code Overview
CPT code 0074U is a Proprietary Laboratory Analyses (PLA) code for the CYP2D6 trans–duplication/multiplication non–duplicated gene targeted sequence analysis developed by the Mayo Clinic Laboratory. This test is a follow-up genetic sequencing assay performed when the initial 0070U test does not determine a patient’s CYP2D6 genotype. The result can affect drug metabolism interpretation for medications metabolized by CYP2D6.
-
Service type: Genetic diagnostic laboratory test (proprietary targeted sequence analysis)
-
Typical site of service: Clinical or reference laboratory setting (specimen collected in outpatient or inpatient settings and analyzed at the performing laboratory)
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A patient referred for pharmacogenetic clarification after initial CYP2D6 testing returned an inconclusive genotype due to suspected copy number variation. The patient is an adult receiving multiple medications metabolized by CYP2D6 (for example, selective serotonin reuptake inhibitors, tricyclic antidepressants, certain opioids, or tamoxifen). The treating clinician (primary care physician, psychiatrist, pain specialist, or oncologist) orders a follow-up targeted assay to resolve gene duplications/multiplications versus non-duplicated alleles. A blood or buccal specimen is collected in an outpatient laboratory or hospital clinical laboratory. The sample is sent to the Mayo Clinic Laboratory for the proprietary test reported with 0074U. Results clarify CYP2D6 allele copy number and inform phenotype assignment (ultrarapid, normal, intermediate, poor metabolizer) which can impact drug selection or dosing. Typical site of service is a hospital-based or independent clinical laboratory, with specimen collection in an outpatient clinic, ambulatory surgery center, or inpatient setting when needed. Documentation in the medical record includes the indication, prior 0070U result showing unresolved genotype, specimen type, and the clinical reason for repeat testing (medication management, adverse reaction history, or treatment optimization).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |